Genzyme's Gaucher disease drug hits main goals in 2 Phase III trials

02/18/2013 | Reuters · Fox Business

Eliglustat tartrate, an experimental drug from Sanofi unit Genzyme, met the primary goals of two late-stage trials involving patients with Gaucher disease. Eliglustat was associated with reductions in spleen size and matched Sanofi's Cerezyme in symptom response. The company plans to use the trials in seeking regulatory approval.

View Full Article in:

Reuters · Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC